AccessClosure of Mountain View, CA is releasing a new version of its Mynx vascular closure device, the Mynx Cadence. When contacted by Medgadget, the company representative told us that the key differences between the Mynx Vascular Closure Device and St. Jude’s popular Angio-Seal system is in the way the femoral artery is closed and in the chemical composition of the sealant. For one, Angio-Seal has a sandwich structure, with a bioabsorbable intravascular anchor. Mynx Cadence, on the other hand, is a complete extravascular closure device. The sealant composition difference between two devices is also important, according to the company. While Angio-Seal uses collagen, a bioactive thrombogenic agent, Mynx deploys inert polyethylene glycol (PEG). And, finally, while Angio-Seal is advertised to dissolve within 60 to 90 days, Mynx is said to be entirely gone within 30 days.
Here are the design changes in the new Mynx Cadence:
Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy. A definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling. Additionally, a single marker on the advancer tube removes any guesswork around sealant compression. Finally, a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation. These changes result in more consistent sealant delivery every time.
The Mynx Vascular Closure Device utilizes a conformable, waterâ€soluble polyethylene glycol (PEG) sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but a healed artery.
Animation demonstrating the previous generation Mynx:
Press release: AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device… (.pdf)